About the Company
iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ITRM News
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
Iterum Therapeutics ITRM jumped 17.8% on Mar 6, 2024, and continued to gain another 3.4% in the after-market hours as it ...
Iterum Therapeutics Provides Business Update
Resubmission of NDA is On Track for First Half of Q2 24Extended Cash Runway into 2025DUBLIN, Ireland and CHICAGO, March 06, 2024 (GLOBE ...
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral ...
Rahul Jain and Gunjan Arora’s ‘Iterum’ on display at Art Centrix Space
Art lovers can head over to Iterum, an art exhibition at Art Centrix Space, New Delhi. The exhibition is the outome of a ...
REFILE-Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows
AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease ...
Loading the latest forecasts...